Paris, France

Frédéric Revah


Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 63(Granted Patents)


Location History:

  • Antony, FR (2003)
  • Paris, FR (2001 - 2004)

Company Filing History:


Years Active: 2001-2004

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Frédéric Revah: Innovator in Neurodegenerative Disease Treatment

Introduction

Frédéric Revah is a prominent inventor based in Paris, France. He has made significant contributions to the field of neurodegenerative diseases, particularly through his innovative patents. With a total of 5 patents, Revah's work focuses on novel methods for treating conditions such as amyotrophic lateral sclerosis.

Latest Patents

One of Revah's latest patents is a method for treating amyotrophic lateral sclerosis. This invention concerns a novel approach to treating motor neuron diseases, specifically through the systemic administration of expression systems of neurotrophic factors. Another significant patent involves recombinant adenoviruses coding for basic fibroblast growth factors (bFGF). This invention includes recombinant adenoviruses that comprise a heterologous DNA sequence coding for bFGF, along with its preparation and uses for the treatment and/or prevention of neurodegenerative diseases.

Career Highlights

Throughout his career, Frédéric Revah has worked with notable companies, including Aventis Pharma S.A. His experience in the pharmaceutical industry has greatly influenced his innovative approaches to treatment.

Collaborations

Revah has collaborated with several professionals in his field, including Jacques Mallet and Françoise Finiels. These collaborations have contributed to the advancement of his research and inventions.

Conclusion

Frédéric Revah's contributions to the treatment of neurodegenerative diseases through his patents highlight his role as an influential inventor. His innovative methods and collaborations continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…